Loading…
← CockpitCompetitor Analysis › 9887.HK Nanjing Leads Biolabs Co., Ltd. Class HOpen in the cockpit ↗

Nanjing Leads Biolabs Co., Ltd. Class H9887.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology

Nanjing-based Chinese biotech developing antibody and bispecific-antibody therapeutics for cancer and autoimmune disease.

Momentum laggard 5
Mkt cap
$764M
US dollars, full cap
Free float
63%
of shares outstanding
$/day
$4.58M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 12.5%
Hurdle
n/a
no reverse DCF
Next earnings
131 days
29 Mar 2027
Close · HKDHK$30.68
1D-4.7%
1W-20.9%
1M-28.6%
3M-56.5%
6M-50.0%
YTD-39.8%
1Y-48.6%
ATR %8.0%
52w lowhigh68.5% off high

What Nanjing Leads Biolabs does

Nanjing-based Chinese biotech developing antibody and bispecific-antibody therapeutics for cancer and autoimmune disease.

Has no marketed drug, so it is paid through licensing: partners hand over an upfront fee and later milestone payments as a drug passes trial stages, while the rest of its funding comes from selling shares. Its bispecific candidates, which bind two targets at once, are what partners are buying.

Products and services

  • Bispecific antibody pipeline
  • Oncology antibody candidates
  • Autoimmune disease pipeline

Customers

  • Global pharma licensing partners

Where it sits in the supply chain

  • Biopharmaceuticals
  • Antibody drug discovery
  • Out-licensing/co-development

What could go right

  • Licensing deal milestone payments

What could go wrong

  • Clinical-stage/no approved products
  • Funding/cash runway risk

Moat: narrow (IP / patents). Proprietary bispecific-antibody platform, but early-stage pipeline with unproven commercial products.

Headquarters: Nanjing, China · Employees: 244

Named competitors

Nanjing Leads Biolabs at a glance

Size Nanjing Leads Biolabs (9887.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $764M, the 647th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$30.68 on 18 Nov 2026.

Performance Over six months the shares fell 50.0%, against -12.2% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 19 in its peer set.

Growth The operating margin is -107.8% (peer median -90.3%).

Valuation It trades at 21.1× enterprise value to sales against a peer median of 6.6× (4th most expensive of 17).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 899887.HK 51
Six months, rebased to 100: Nanjing Leads Biolabs against the median of its 20 peers (local-currency closes).

Nanjing Leads Biolabs financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$235MHK$192MHK$0HK$9.80MHK$0
Revenue growth——-100%——
Gross profitn/an/a-HK$28.2M-HK$20.1M-HK$20.2M
EBITDA-HK$229M-HK$188M-HK$268M-HK$264M-HK$223M
Net income-HK$302M-HK$229M-HK$327M-HK$400M-HK$327M
Free cash flown/a-HK$184M-HK$138M-HK$233M-HK$84.7M
Capital expendituren/aHK$11.3MHK$3.23MHK$13.0MHK$33.9M
Total debtn/aHK$312MHK$284MHK$1.51BHK$1.35B

Quarterly statements and history in the cockpit →

Nanjing Leads Biolabs competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%-25%0%+25%+50%IVASNDXGLUE688526AURA002038MGTXATTO7729996645879887.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Nanjing Leads Biolabs is the large dot.

Nanjing Leads Biolabs competitors and peer comparison

Head to head with its named competitors (9887.HK vs 9926.HK vs 1801.HK vs 9966.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Nanjing Leads Biolabs 9887.HK$764M-50%n/a-108%21.1×n/a
Akeso 9926.HK$7.01B-48%+42%-25%12.9×n/a
Innovent Biologics 1801.HK$18.9B+4%+43%17%7.3×11.6%
Alphamab Oncology 9966.HK$666M-38%-32%-38%6.7×n/a
RemeGen 9995.HK$6.07B-28%+293%61%4.4×-6.8%

How Nanjing Leads Biolabs compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nanjing Leads Biolabs against its 20 peers (data as of 18 Nov 2026)
Measure9887.HKPeer medianRank in peer set
1-month return-28.6%-6.2%2nd lowest of 21
6-month return-50.0%-12.2%3rd lowest of 19
Distance from 52-week high-68.5%-44.9%lowest of 21
Operating margin-107.8%-90.3%9th highest of 17
EV / Sales21.1×6.6×4th most expensive of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
MeiraGTx MGTXUnited States$813M-13%+1,366%44%1.9×n/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%4.1×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Verastem VSTMUnited States$866M+66%+650%-194%8.2×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Peptidream 4587.TJapan$878M-3%+14%-18%6.6×n/an/a

Questions

Who are Nanjing Leads Biolabs's main competitors?
Named competitors: Akeso (9926.HK), Innovent Biologics (1801.HK), Alphamab Oncology (9966.HK), RemeGen (9995.HK). The cockpit's measured peer set (industry) also includes Inventiva (IVA.PA), Syndax Pharmaceuticals (SNDX), Monte Rosa Therapeutics (GLUE), Wuhan Keqian Biology (688526.SS), Aura Biosciences (AURA), Beijing SL Pharmaceutical (002038.SZ).
Is Nanjing Leads Biolabs expensive compared with its peers?
On ev / sales it trades at 21.1× against a peer median of 6.6×, 4th most expensive of 17 in its peer set.
How has Nanjing Leads Biolabs stock performed?
Over six months to 18 Nov 2026 the shares returned -50.0% against -12.2% for the median peer; over one year -48.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.